A Phase I Study for Safety and Tolerability of AL002.

Healthy Clinical Trial

Official title:

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL002 in Healthy Participants and in Participants With Mild to Moderate Alzheimer's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03635047
• Other study ID #: AL002-1
• Status: Completed
• Phase: Phase 1
• Start date: November 12, 2018
• Est. completion date: November 25, 2020

Study information

• Verified date: December 2020
• Source: Alector Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-centre, randomized, double-blind, placebo-controlled, dose escalation first in human (FIH) study in healthy adults and in patients with mild to moderate Alzheimer's disease. The study is designed to systematically assess the safety (including immunogenicity) and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AL002.

Description:

The study will be conducted in 2 phases: In the single ascending dose (SAD) phase up to approximately 56 healthy adult participants will be sequentially enrolled into up to approximately 9 cohorts In the multiple-dose (MD) phase, approximately 32 patients with mild to moderate Alzheimer's disease will be enrolled in three cohorts.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 69
• Est. completion date: November 25, 2020
• Est. primary completion date: August 3, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Total body weight between 50 and 120 kg, inclusive.

2. Clinical laboratory evaluations (including chemistry panel fasted [fasted at least 8 hours], complete blood count (CBC), and urine analysis) within the reference range for the test laboratory, unless deemed not clinically significant by the Investigator. A count of the segmented neutrophils and bands should be performed when results from the white blood cells (WBCs) are not within the reference range.

3. Negative test for selected drugs of abuse at screening (does not include alcohol) and at admission (testing at admission does include alcohol breath test). A positive result may be verified by re-testing (up to one false positive result permitted) and may be followed up at the discretion of the Investigator.

4. Females must be non-pregnant and non-lactating, and either surgically sterile

5. In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), laboratory tests, and vital signs. For MD cohort

1. Ages 50-85 years, inclusive.

2. The participant should be capable of completing assessments alone, per local guidelines.

3. Availability of a person ("study partner") who, in the Investigator's judgment, has frequent and sufficient contact with the participant and is able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits, which require partner input for scale completion, and signs the necessary consent form, per local guidelines.

4. Clinical diagnosis of probable Alzheimer's disease dementia based on National Institute on Aging Alzheimer's Association criteria.

Exclusion Criteria:

1. Pregnant or lactating, or intending to become pregnant within 16 weeks after last dose of study drug.

2. Participation in a clinical trial within 30 days before randomization; use of any experimental oral therapy within 30 days or 5 half-lives prior to Day 1, whichever is greater; or use of any biologic therapy within 12 weeks or 5 half-lives prior to Day 1, whichever is greater. Participants who have received an experimental therapy that has no half-life, like a vaccine, should have completed that therapy at least 12 weeks prior to Day 1. Participants who have received an experimental vaccine against a central nervous system (CNS) target, such as beta-amyloid or tau, are not eligible for this study.

3. Any non-experimental vaccine within 2 weeks of randomization, until 2 weeks after the last dose. It is advised that prospective participants receive their annual influenza vaccine as early as possible in advance of the flu season, and then wait 2 weeks prior to randomization. It is permitted to receive the annual influenza vaccine during the screening period.

4. Surgery or hospitalization during the 4 weeks prior to screening.

5. Planned procedure or surgery during the study.

6. Systemically, clinically significantly immunocompromised patients, owing to continuing effects of immune suppressing medication.

7. Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.

8. Past history of seizures, with the exception of childhood febrile seizures.

Related Conditions & MeSH terms

• Alzheimer Disease
• Healthy

Intervention

Biological:
• AL002
Single-doses of AL002 in up to 9 dose-escalating cohorts

Other:
• Saline Solution
Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects for HV and 10 active and 2 placebo for patients

Locations

Country	Name	City	State
Australia	Nucleus Network Pty Ltd	Melbourne
United Kingdom	University College London	London
United States	Brain Matters Research	Delray Beach	Florida
United States	Columbia University	New York	New York
United States	Compass Research - Orlando	Orlando	Florida
United States	Compass Research - The Villages	The Villages	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Alector Inc.

Countries where clinical trial is conducted

United States,  Australia,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of safety and tolerability of AL002 measured by number of subjects with adverse events and Dose Limiting Adverse Event (DLAEs)	Incidence of adverse events and dose limiting Adverse Events during the DLAE observation period and/or study treatment periods.	141 days
Secondary	Pharmacokinetics (PK) of AL002	Serum and CSF concentration of AL002 at specified time points	85 days
Secondary	Maximum plasma concentration (Cmax) for AL002	Evaluate Cmax for serum and CSF concentration of AL002 at specified time points	85 days
Secondary	Area under the curve concentration (AUC) for AL002	Evaluate AUC for serum and CSF concentration of AL002 at specified time points	85 days